Navigation Links
Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis

icantly reduced in the COPAXONE(r) plus minocycline group (0.19 versus 0.41; p=NS).

About COPAXONE(r)

Current data suggest COPAXONE(r) (glatiramer acetate injection) is a selective MHC class II modulator. COPAXONE(r) is indicated for the reduction of the frequency of relapses in RRMS. The most common side effects of COPAXONE(r) are redness, pain, swelling, itching, a lump or an indentation at the site of injection, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness.

COPAXONE(r) is now approved in 47 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In Europe, COPAXONE(r) is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. In North America, COPAXONE(r) is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA). COPAXONE(r) is a registered trademark of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

-more-

GA Minocycline/Page 3

See additional important information at http://www.copaxone.com/pi/index.html <http://www.copaxone.com/pi/index.html> or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.

Safe Harbor Statement under the U. S. Private Securit
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

Post Your Comments:
(Date:11/20/2009)...RANKLIN LAKES, N.J., Nov. 20 /PRNewswire-FirstCall...DX ) today announced the completion of its acquisi...ed company that develops and manufactures molecula..., In May 2009, BD and HandyLab announced an exclus...molecular assays on the HandyLab Jaguar(TM) platfo...
(Date:11/20/2009)... PRINCETON, N.J., Nov. 20 /PRNewswire-FirstCall/ -...genix or the Company), formerly known as DOR BioPh...nounced today that it has formed a consortium to d...) and other rapidly acting vaccines. Soligenix rec...tute of Allergy and Infectious Diseases (NIAID), a...
(Date:11/19/2009)... BIRMINGHAM, Ala., Nov. 19 /PRNewswire-FirstCall/ ... today announced the pricing of a public offering ...er share, resulting in gross proceeds of $48.75 mi...Cryst pursuant to an effective shelf registration ... Exchange Commission. BioCryst has also granted t...
Breaking Medicine Technology:BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Digital Healthcare Specialist Cadient Group Ranked 232 on List of Full service Advertising Agencies in the Philadelphia Region 12623 1Digital Healthcare Specialist Cadient Group Ranked 232 on List of Full service Advertising Agencies in the Philadelphia Region 12623 2American Chemical Society weekly presspac June 10 2009 8824 1American Chemical Society weekly presspac June 10 2009 8824 2American Chemical Society weekly presspac June 10 2009 8824 3American Chemical Society weekly presspac June 10 2009 8824 4American Chemical Society weekly presspac June 10 2009 8824 5American Chemical Society weekly presspac June 10 2009 8824 6American Chemical Society weekly presspac June 10 2009 8824 7Scientific Study Makes it Possible to Measure Connection Between People 48880 1Scientific Study Makes it Possible to Measure Connection Between People 48880 2Scientific Study Makes it Possible to Measure Connection Between People 48880 3
...t Americans know their cholesterol level, but do t...ch findings from Dr. Paul A. Gurbel, an interventi... for Thrombosis Research based at Sinai Hospital o... "stickiness" may be the single largest factor in ...omplications, including heart attack, in patients ...
...ell Therapeutics (CTI),(Nasdaq and MTA: CTIC) anno...,and Drug Administration (FDA), CTI expects to beg...DA) and request priority review for pixantrone to ...NHL) in the first quarter of 2009.,If granted prio...re the end of,2009. , "This communication from...
Other Medicine Technology:New Research Suggests Platelet 'Stickiness' May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease 2Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission 2Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission 3
(Date:11/23/2009).../--Thistimeofyearbringslotsofcheerbutalsoitsfairsh...iveandnegative,translateintourgestoovereatasawayof...odosoallseasonlong. ,, Wemaythinkweareonlygoing...ere?"Thatpieoftenopensthefloodgatestocravings,andm...lingourselvestohavejustonelittletreat.Insteadwebin...
(Date:11/23/2009)...derlines Moravia,s Commitment to the UK and Irish ...ublic (PRWEB) November 23, 2009 -- Moravia Worldwi...ounced today the appointment of George Krawczyk as...w position, he will lead the established business ...ll responsibility for managing existing customers ...
(Date:11/23/2009)...ontics, Ltd. (Tonawanda, N.Y.) offers DentaSOAK&re...to kill more than 99% of infection-causing bacteri... Tonawanda, NY (PRWEB) November 23, 2009 ...found that mouthguards used regularly are highly c...staph to strep to pneumococci. The results of the ...
(Date:11/22/2009)...edical Center is among 10 institutions selected by...llion over five years as part of the Inner City As...ves funding through the NIH,s National Institute o...vel treatments and causes of asthma in urban child...d immunology at UT Southwestern, said continued fu...
(Date:11/22/2009)...tists from Weill Cornell Medical College have disc...a powerful target for the treatment of non-Hodgkin...ytes, or white blood cells. By exploiting this mec...uppress tumor formation in lab testing and in anim...esign of a clinical trial that will soon be under ...
Breaking Medicine News(10 mins):Health News:Tis' the Season to Eat and Eat More! 2Health News:Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 2Health News:DentaSOAK Dental Cleaner Reduces Infection Risk Linked to Mouthguards 2Health News:UT Southwestern receives continued NIH funding for Inner City Asthma Consortium 2Health News:New cancer target for non-Hodgkin's lymphoma 2
...unya', a viral fever common in Africa, has struck ... Tamil Nadu, prompting health department officials...e, which could have been transmitted by 'aedes mos...trict about 700 people had been affected in S.P.Pa...
...s of loss of jobs on the NHS worsened today after ...ffer services that only fit into its budget.// The...ry. It said that compulsory job losses canno...ctor and this number could only double by the end ...
...eading all-rounder Jacques Kallis will undergo sur...t has plagued him since November last year.// ...rced out of last year's tour of Australia because ...a in September and the 2007 World Cup in West Indi...
...lth Organization director-general Dr. Lee Jong-woo...h could be the blood clot in his brain//. He was u...sful. Dr. Lee Jong-wook who is 61 years old suffer...became WHO director-general in 2003. During his te...
...sbane and Women's Hospital (RBWH), Sydney struggle...um where nearly 19 patients// in three wards were ...nt Acinetobacter baumannii (CRAB) on their skin. ...ncess Alexandra Hospital. Patients from both ...
... Government may go in for an immunisation campaign...booster dose of measles vaccine. // Though t...hildren in state-run hospitals, the government wan... soon after completion of the ongoing second round...
Other Medicine News:
...(Cl) ≤ 3000 mg/kg sulfate (SO 4 ) ≤ 60...8804; 10 mg/kg Co ≤ 10 mg/kg Cr ≤ 10 m...804; 500 mg/kg Mg ≤ 10 mg/kg Mn ≤ 10 m...≤ 10 mg/kg Zn ≤ 10 mg/kg Special grad...
...ose agarose, has been developed for analytical and...separation of high molecular weight DNA [pulsed-fi...igh gel strength agarose ( 1800 g/cm2, 1%). Th...rations of agarose in electrophoretic gels. The ag...
Agarose, high gel strength, Molecular Biology Grade
UltraClean™ Forensic Agarose
Medicine Products: